Skip to main content

Advertisement

Table 5 Tumor marker analysis in the cases with and without cholangiocarcinoma

From: Ultrasound screening for cholangiocarcinoma could detect premalignant lesions and early-stage diseases with survival benefits: a population-based prospective study of 4,225 subjects in an endemic area

Predictor Cholangiocarcinoma Total Sensitivity Specificity PPV NPV
Positive Negative
Positive CA19-9 6 59 65 18.75 98.63 9.23 99.39
Negative CA19-9 26 4245 4271
Total 32 4304 4336
Positive CEA 11 749 760 34.38 82.60 1.45 99.41
Negative CEA 21 3555 3576
Total 32 4304 4336
Positive ALP 15 641 656 50.00 83.54 2.29 99.54
Negative ALP 15 3254 3269
Total 30 3895 3925
Positive CA19-9 or CEA or ALP 22 1252 1274 68.75 70.91 1.73 99.67
Negative CA19-9 or CEA or ALP 10 3052 3062
Total 32 4304 4336
  1. Abbreviations: CA19-9 carbohydrate antigen 19–9, CEA carcinoembryonic antigen, ALP alkaline phosphatase, NPV negative predictive value, PPV positive predictive value